Artificial Intelligence (AI)-driven biomarker discovery innovators Scailyte and Volv Global, today announced a strategic partnership to develop a patient identification and diagnostic platform for rare diseases.
See Press Release at Newswire
The companies join their unprecedented expertise in data analysis: Volv Global identifies digital disease biomarkers by screening patient electronic health records (EHRs) with a unique automated disease learning platform, inTrigue and Scailyte leverages a best-in-class single-cell data analysis platform, ScaiVision, to identify and validate disease-specific molecular biomarkers.
Through the joint venture, Volv Global will identify potential patients with rare or difficult to diagnose diseases, who can then be enrolled in molecular biomarker discovery studies led by Scailyte and clinical key opinion leaders in the disease area.
The benefits of these joint efforts will be multifaceted: undiagnosed or misdiagnosed patients will be treated appropriately much earlier; clinicians will have tools for an informed diagnosis and pharmaceutical companies will be able to provide therapies to the target population with high response rates.
Peter Nestorov, PhD, CEO of Scailyte commented: “One of the key challenges with oncological and immunological diseases is their biological complexity. So to diagnose these diseases accurately and stratify the patients, a multi-parametric approach is needed – one that combines molecular readouts with clinical data and a smart algorithm to support clinicians in their decisions. I am excited that the Volv-Scailyte partnership addresses this major clinical need in a holistic way and has the potential to make a difference for millions of undiagnosed or misdiagnosed patients.”
Christopher Rudolf, CEO of Volv Global added: “We are learning more and more about rare diseases, for example, that what might once have been thought of as a single rare disease is actually multiple rare diseases that have been classified under a single category. This is why so many patients remain undiagnosed or misdiagnosed. The partnership between Volv and Scailyte has the potential to dramatically improve the journey to diagnosis and treatment for patients. The synergies between our two companies offer an important value proposition to patients, clinicians and pharma companies.”
Scailyte AG is a spin-off of ETH Zurich and combines single-cell technologies, high-quality datasets and machine learning methods to identify disease-specific biomarkers, with focus on oncology and immunology. Scailyte’s proprietary best-in-class data analysis platform ScaiVision associates multimodal single-cell datasets (RNA-/TCR-/BCR-seq, proteomics, etc) with clinical endpoints, such as disease diagnosis, progression, severity, treatment response, in order to identify ultra-sensitive biomarker signatures. Thanks to the single-cell resolution and AI-driven approach, ScaiVision is the most powerful and cutting-edge approach to precise diagnosis and prediction of therapy response. Scailyte leverages a broad network of top clinicians to identify clinical indications with high unmet clinical needs and collaborates with global pharmaceutical and biotech companies to translate the novel biomarkers into ultra-sensitive companion diagnostics (CDx) or IVD assays. For more information, visit www.scailyte.com and connect on social media @LinkedIn and @Twitter.
Volv is a Swiss AI and applied data science company based in Lausanne that produces solutions to address key critical issues in Healthcare for today and tomorrow. We develop differentiated Artificial Intelligence methodologies addressing a defined set of problems in healthcare, and have solutions that are targeted on rare diseases, personalised medicines, and difficult-to-diagnose diseases with the product inTrigue. Volv also focus on cognitive disorders with inCognita, and chronic disease management solutions with inVerse. With unique tools, including some that are focused on finding weak signals in sparse, unstructured, and structured data, Volv has a unique position in the Artificial Intelligence landscape. This allows us to focus on tangible economic and healthcare outcomes by differentiating patient cohorts and symptoms in a novel way that is required for the next generation of healthcare and the change in population dynamics that we see evolving. Volv’s toolsets are repeatable solutions that can fit into any data environment and allow rapid return on investment for our customers, building to longer term strategic partnerships. For more information, visit Volv Global website: www.volv.global.